Braidwell LP Acquires 73,272 Shares of Repligen Co. (NASDAQ:RGEN)

Braidwell LP increased its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 22.6% during the third quarter, Holdings Channel.com reports. The fund owned 396,781 shares of the biotechnology company’s stock after purchasing an additional 73,272 shares during the quarter. Repligen accounts for about 1.7% of Braidwell LP’s holdings, making the stock its 23rd biggest position. Braidwell LP’s holdings in Repligen were worth $59,049,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of RGEN. Lazard Asset Management LLC increased its position in Repligen by 206.1% during the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 136 shares during the period. B. Riley Wealth Advisors Inc. increased its holdings in Repligen by 12.6% in the 1st quarter. B. Riley Wealth Advisors Inc. now owns 1,450 shares of the biotechnology company’s stock valued at $267,000 after buying an additional 162 shares during the period. Tidal Investments LLC increased its holdings in Repligen by 11.6% in the 1st quarter. Tidal Investments LLC now owns 1,421 shares of the biotechnology company’s stock valued at $261,000 after buying an additional 148 shares during the period. Virtu Financial LLC increased its holdings in Repligen by 29.3% in the 1st quarter. Virtu Financial LLC now owns 1,545 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 350 shares during the period. Finally, Swedbank AB bought a new position in Repligen in the 1st quarter valued at about $5,518,000. 97.64% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have commented on RGEN shares. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a report on Friday, November 22nd. Wells Fargo & Company started coverage on shares of Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price on the stock. Wolfe Research started coverage on shares of Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating on the stock. Benchmark reissued a “hold” rating on shares of Repligen in a report on Monday, August 5th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $190.25.

Insider Activity

In other news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. This trade represents a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.20% of the company’s stock.

Repligen Trading Up 2.2 %

Shares of NASDAQ RGEN opened at $149.99 on Friday. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $211.13. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The company has a 50 day simple moving average of $140.83 and a 200 day simple moving average of $142.94.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.09. The firm had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.23 earnings per share. Equities research analysts anticipate that Repligen Co. will post 1.52 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.